EURAZEO'S KURMA PARTNERS SECURES €215 MILLION FOR BIOFUND IV

Kurma Partners, a healthcare venture capital firm under the Eurazeo group, has finalized its Biofund IV with a closing of €215 million. This fund aims to deliver transformative therapeutic solutions for serious diseases, continuing the strategy of its predecessor, Biofund III. The fundraising success underscores robust support from investors, including CSL, the European Investment Fund, Bpifrance, and other European entities.

Biofund IV targets around 20 investments, fostering startups and new biotech creations. Already, 11 investments have been made in diverse areas such as autoimmune diseases, cancer immunotherapy, and genetic heart diseases. Kurma's strategy leverages partnerships with Argobio Studio and European research networks to bridge scientific discovery and venture capital. This approach reflects the evolving landscape of European biotech, enhancing its competitiveness and innovation capacity.